http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8637038-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8bb2c65fed767c6cdb08ca3b49dbb9f0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9b077f6266e6d5c06bb0440f910bd44f http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a1e455f4118fb02f884a8812aacc9dda |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-436 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N43-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| filingDate | 2012-04-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7cc323d5f5187d419173318f3568508e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8972d1fe780d7e62e977e4ff372ed9f5 |
| publicationDate | 2014-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-8637038-B2 |
| titleOfInvention | Methods for inhibiting allograft rejection |
| abstract | Disclosed herein are methods for treating or inhibiting allograft rejection in a transplant recipient. In some embodiments, the methods include administering to the transplant recipient a first amount of a JAK1/3 inhibitor comprising 5-(2-(4-fluoro-3-methoxy-5-methylphenylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-one (Compound I) or a prodrug thereof and administering to the transplant recipient a second amount of a non-JAK1/3 inhibitor immunosuppressant, wherein the combined effect of the first amount and the second amount is greater than the effect of the first amount or the second amount individually, wherein the JAK1/3 inhibitor acts in combination with the non-JAK1/3 inhibitor immunosuppressant to inhibit or treat allograft rejection. In some embodiments at least one of the first amount or the second amount is individually a suboptimal dose for inhibiting or treating allograft rejection. In some examples, the combined effect of the first amount and the second amount to inhibit or treat allograft rejection in the transplant recipient is synergistic. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-RE47396-E |
| priorityDate | 2011-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 747.